Dr. Paula Wells is a consultant oncologist specializing in the management of genitourinary (bladder and prostate) and thoracic (lung and mesothelioma) malignancies. She has expertise in all non-surgical treatments, including chemotherapy, immunotherapy, biological and targeted therapies, and state-of-the-art radiotherapy techniques such as IGRT, IMRT, 4D CT, and Stereotactic Radiotherapy (SABR and SRS) using both Cyberknife and Linear accelerator platforms. She also has extensive experience in low dose rate brachytherapy (LDR) for prostate cancer management.

Dr. Wells completed her oncology training at St. Bartholomew's, UCLH, and Mount Vernon Hospitals. She undertook a postgraduate research degree at Imperial College School of Medicine, Hammersmith, investigating the potential of PET to demonstrate the biological effects of chemotherapy, for which she received several awards and a PhD. She completed her post-doctoral training at the Royal Marsden with the Academic Urology Unit.

Dr. Wells has been extensively involved in the development of genitourinary and thoracic cancer services for the North East London Cancer Network. She has an active trial portfolio of UK clinical trials and is the principal investigator for several pivotal radiotherapy studies. She has led the development of IMRT for prostate cancer, chemo-radiation in bladder and lung cancer, and Stereotactic Radiotherapy (SABR). Her research interests in PET continue to develop, focusing on the direct effects of radiotherapy on tissue and the integration of novel therapies with radiation.